- Home
- BSII vs THRD Comparison
BSII vs THRD Comparison
Compare BSII & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSII
- THRD
- Stock Information
- Founded
- BSII 2024
- THRD 2019
- Country
- BSII Hong Kong
- THRD United States
- Employees
- BSII N/A
- THRD N/A
- Industry
- BSII
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- BSII
- THRD Health Care
- Exchange
- BSII Nasdaq
- THRD Nasdaq
- Market Cap
- BSII 194.7M
- THRD 164.2M
- IPO Year
- BSII 2024
- THRD 2022
- Fundamental
- Price
- BSII $10.26
- THRD $5.15
- Analyst Decision
- BSII
- THRD Hold
- Analyst Count
- BSII 0
- THRD 3
- Target Price
- BSII N/A
- THRD $5.00
- AVG Volume (30 Days)
- BSII 319.0K
- THRD 1.1M
- Earning Date
- BSII 01-01-0001
- THRD 05-08-2025
- Dividend Yield
- BSII N/A
- THRD N/A
- EPS Growth
- BSII N/A
- THRD N/A
- EPS
- BSII N/A
- THRD N/A
- Revenue
- BSII N/A
- THRD N/A
- Revenue This Year
- BSII N/A
- THRD N/A
- Revenue Next Year
- BSII N/A
- THRD N/A
- P/E Ratio
- BSII $106.07
- THRD N/A
- Revenue Growth
- BSII N/A
- THRD N/A
- 52 Week Low
- BSII $9.85
- THRD $3.18
- 52 Week High
- BSII $10.39
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- BSII N/A
- THRD 76.76
- Support Level
- BSII N/A
- THRD $5.11
- Resistance Level
- BSII N/A
- THRD $5.25
- Average True Range (ATR)
- BSII 0.00
- THRD 0.05
- MACD
- BSII 0.00
- THRD -0.04
- Stochastic Oscillator
- BSII 0.00
- THRD 27.54
About BSII Black Spade Acquisition II Co Class A Ordinary Share
Black Spade Acquisition II Co is a blank check company.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.